Drugs / 68Ga-Her2-affibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06289517 | May 2024 → Jul 2025 overdue | neoplasm | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-Her2-affibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06289517 ↗ |
| Route | Intravenous | “injected intravenously” NCT06289517 ↗ |